Different breast cancer subtypes (Luminal A, Luminal B, Her2+, and TNBC) show unique immune cell types with distinct gene expressions, suggesting dynamic immune interactions with ER, PR and Her2 status between subtypes 5, which can further indicates differential prognosis6. This evidence concerns the gene ESR1 and breast carcinoma.